Varenicline + Prazosin for Heavy Drinking Smokers

Status Completed

Clinical Trial Summary

The purpose of this study is to examine the effect of varenicline and prazosin on smoking, drinking, and sleep among cigarette smokers who report heavy alcohol use. Varenicline is an FDA approved smoking cessation medication. Some smokers report sleep problems when taking varenicline. This study will test whether using prazosin, which is an FDA-approved blood pressure medication, in combination with varenicline reduces sleep problems that can be associated with using varenicline for smoking cessation. In addition, the study will examine the combined effects of these medications on smoking and drinking.

Hypothesis: Varenicline plus prazosin will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than varenicline alone prior to the 3-day practice quit attempt.

Hypothesis: Varenicline plus prazosin will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than varenicline alone during the 3-day practice quit attempt.

Clinical Trial Description

The study comprises an 8-week double-blind, within-subjects, crossover design of varenicline (up to 2mg per day) plus either prazosin (up to 8mg per day) (V+P) or placebo (V) with 20 heavy drinking smokers. Each medication phase is 3 weeks with a 2-week medication washout in between. Participants are asked to make a practice quit attempt for 3 days the last week of each medication phase.

This is an exploratory study to look at two primary aims:

1. Evaluate the effect of prazosin on sleep disturbance caused by varenicline in heavy drinking smokers prior to quitting smoking.

Hypothesis: V+P will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than V alone.

2. Evaluate the effect of prazosin on sleep disturbance caused by varenicline during smoking cessation in heavy drinking smokers.

Hypothesis: V+P will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than V alone We will also investigate the combined effects of prazosin and varenicline on smoking behavior (i.e., smoking urge) and alcohol consumption (i.e., drinks per drinking day) as exploratory aims. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02193256
Study type	Interventional
Source	Yale University
Contact
Status	Completed
Phase	Early Phase 1
Start date	July 2014
Completion date	June 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04043728` - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Active, not recruiting	`NCT02643914` - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings	N/A
Recruiting	`NCT02422914` - Benefits of Tobacco Free Cigarette	N/A
Active, not recruiting	`NCT02629679` - Sports, Education and Consumption of Substances in Adolescents	N/A
Completed	`NCT02385227` - Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes	N/A
Completed	`NCT02218281` - Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation	N/A
Completed	`NCT01199380` - Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms	Phase 2
Completed	`NCT00802919` - Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors	Phase 4
Completed	`NCT01692353` - Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers	N/A
Completed	`NCT00756704` - The Effectiveness of Smoking Cessation Guidelines in the Emergency Department	N/A
Completed	`NCT01081119` - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth	Phase 2
Completed	`NCT00682474` - School Nurse-Delivered Smoking Cessation Intervention	Phase 2/Phase 3
Active, not recruiting	`NCT05520775` - Semaglutide for Alcohol Use Disorder	Phase 2
Terminated	`NCT03840694` - Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior	N/A
Not yet recruiting	`NCT06032793` - Effects of Deep Breathing Exercise on Pulmonary Function, Perceived Stress and Physical Fitness.	N/A
Terminated	`NCT03326128` - High Dose Bupropion for Smoking Cessation - Pilot Study	Phase 2
Recruiting	`NCT03218670` - Your Health in On Click	N/A
Completed	`NCT02538042` - Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)	N/A
Completed	`NCT02792426` - Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.